Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva

12 Jan 2024

Abstract excerpt

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder characterized by episodic yet cumulative heterotopic ossification (HO) of skeletal muscles, tendons, ligaments, and fascia. FOP arises from missense mutations in Activin Receptor type I (ACVR1), a type I bone morphogenetic protein (BMP) receptor. Although initial findings implicated constitutive activity of FOP-variant ACVR1 (ACVR1FOP) and/or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heterotopic Ossification and Related Conditions
Share to Medical Imaging and Pathology Studies
Share to Parathyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38254701
DOI: 10.3390/biom14010101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans ProgressivaPMID 38254701Read ↗

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.Semantic proximity Read ↗

The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.Semantic proximity Read ↗

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-DependentSemantic proximity Read ↗

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro/adipogenic progenitors in fibrodysplasia ossificans progressiva miceSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.Semantic proximity Read ↗

Clinical Aspects and Current Therapeutic Approaches for FOPSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva emerges from obscurity.Semantic proximity Read ↗

From mysteries to medicines: drug development for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva: a blueprint for metamorphosisSemantic proximity Read ↗

Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.